These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 15508021)

  • 21. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
    Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
    J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor-G protein coupling and Gbetagamma signaling.
    Wang HY; Friedman E; Olmstead MC; Burns LH
    Neuroscience; 2005; 135(1):247-61. PubMed ID: 16084657
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of low-dose naloxone infusion on fentanyl requirements in critically ill children.
    Darnell CM; Thompson J; Stromberg D; Roy L; Sheeran P
    Pediatrics; 2008 May; 121(5):e1363-71. PubMed ID: 18411237
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of agonist and antagonist effects of tramadol in opioid-dependent humans.
    Carroll CP; Walsh SL; Bigelow GE; Strain EC; Preston KL
    Exp Clin Psychopharmacol; 2006 May; 14(2):109-20. PubMed ID: 16756415
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Naloxone, meperidine, and shivering.
    Kurz M; Belani KG; Sessler DI; Kurz A; Larson MD; Schroeder M; Blanchard D
    Anesthesiology; 1993 Dec; 79(6):1193-201. PubMed ID: 8267194
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhancement mu opioid antinociception by oral delta9-tetrahydrocannabinol: dose-response analysis and receptor identification.
    Cichewicz DL; Martin ZL; Smith FL; Welch SP
    J Pharmacol Exp Ther; 1999 May; 289(2):859-67. PubMed ID: 10215664
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interactions between the discriminative stimulus effects of mu and kappa opioid agonists in the squirrel monkey.
    Negus SS; Picker MJ; Dykstra LA
    J Pharmacol Exp Ther; 1991 Jan; 256(1):149-58. PubMed ID: 1846412
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ultra-low dose naloxone restores the antinociceptive effect of morphine in pertussis toxin-treated rats by reversing the coupling of mu-opioid receptors from Gs-protein to coupling to Gi-protein.
    Tsai RY; Tai YH; Tzeng JI; Cherng CH; Yeh CC; Wong CS
    Neuroscience; 2009 Dec; 164(2):435-43. PubMed ID: 19682558
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mu opiate receptor gene dose effects on different morphine actions: evidence for differential in vivo mu receptor reserve.
    Sora I; Elmer G; Funada M; Pieper J; Li XF; Hall FS; Uhl GR
    Neuropsychopharmacology; 2001 Jul; 25(1):41-54. PubMed ID: 11377918
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Methadone restores local and remote EEG functional connectivity in opioid-dependent patients.
    Fingelkurts AA; Fingelkurts AA; Kivisaari R; Autti T; Borisov S; Puuskari V; Jokela O; Kähkönen S
    Int J Neurosci; 2009; 119(9):1469-93. PubMed ID: 19922368
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Unlimited access to heroin self-administration: independent motivational markers of opiate dependence.
    Chen SA; O'Dell LE; Hoefer ME; Greenwell TN; Zorrilla EP; Koob GF
    Neuropsychopharmacology; 2006 Dec; 31(12):2692-707. PubMed ID: 16452993
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antagonism of delta(2)-opioid receptors by naltrindole-5'-isothiocyanate attenuates heroin self-administration but not antinociception in rats.
    Martin TJ; Kim SA; Cannon DG; Sizemore GM; Bian D; Porreca F; Smith JE
    J Pharmacol Exp Ther; 2000 Sep; 294(3):975-82. PubMed ID: 10945849
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overdoses due to fentanyl and its analogues (F/FAs) push naloxone to the limit.
    Pergolizzi JV; Dahan A; Ann LeQuang J; Raffa RB
    J Clin Pharm Ther; 2021 Dec; 46(6):1501-1504. PubMed ID: 34111307
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of relative intrinsic activity of mu-opioid analgesics in vivo by using beta-funaltrexamine.
    Adams JU; Paronis CA; Holtzman SG
    J Pharmacol Exp Ther; 1990 Dec; 255(3):1027-32. PubMed ID: 2175793
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of intravenous buprenorphine and methadone self-administration by recently detoxified heroin-dependent individuals.
    Comer SD; Sullivan MA; Walker EA
    J Pharmacol Exp Ther; 2005 Dec; 315(3):1320-30. PubMed ID: 16144974
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Behavioral depression induced by an amygdala seizure and the opioid fentanyl was mediated through the nucleus accumbens.
    Long JJ; Ma J; Leung LS
    Epilepsia; 2009 Aug; 50(8):1953-61. PubMed ID: 19490038
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of a single 50% extra dose of methadone on heroin craving and mood in lower- versus higher-dose methadone patients.
    Strasser J; Wiesbeck GA; Meier N; Stohler R; Dürsteler-Macfarland KM
    J Clin Psychopharmacol; 2010 Aug; 30(4):450-4. PubMed ID: 20571436
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A history of sexual, emotional, or physical abuse predicts adjustment during opioid maintenance treatment.
    Branstetter SA; Bower EH; Kamien J; Amass L
    J Subst Abuse Treat; 2008 Mar; 34(2):208-14. PubMed ID: 17596905
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chronic agonist treatment converts antagonists into inverse agonists at delta-opioid receptors.
    Liu JG; Prather PL
    J Pharmacol Exp Ther; 2002 Sep; 302(3):1070-9. PubMed ID: 12183665
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of irreversible antagonists to determine the relative efficacy of mu-opioids in a pigeon drug discrimination procedure: comparison of beta-funaltrexamine and clocinnamox.
    Barrett AC; Smith ES; Picker MJ
    J Pharmacol Exp Ther; 2003 Jun; 305(3):1061-70. PubMed ID: 12649297
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.